| REVIEW ARTICLE |
|
| Year : 2023 | Volume
: 34
| Issue : 2 | Page : 55-63 |
|
|
Treatment of benign prostatic hyperplasia: Update and future
Tai-Hua Chiu1, Yi-Hsuan Wu2, Yung-Chin Lee3
1 Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
2 Department of Urology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
3 Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University; Department of Urology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University; Kaohsiung Medical University, Kaohsiung, Taiwan
Correspondence Address:
Yung-Chin Lee
100, Shih-Chua 1st Road, Sanmin, Kaohsiung 807
Taiwan
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/UROS.UROS_134_22
|
|
|
Benign prostatic hyperplasia (BPH) is one of the widespread diseases affecting aging males globally. As prostatic cell proliferation, it clinically influences a great degree of bladder outlet obstruction and is characterized by bothersome lower urinary tract symptoms. Assessments and treatments should not only be conducted based on the prostate volume or condition, related symptoms and quality of life should be considered also. The present analysis focuses on the update of management for BPH, including pharmacotherapy and slightly invasive surgical options. Despite alpha-1 adrenoceptor antagonists, many other factors and even combination therapy were extensively studied. Regarding slightly invasive surgical treatments, including Aquablation, water vapor thermal therapy, prostatic artery embolization, prostatic urethral lift, and nitinol butterfly-like stent, we analyzed the latest findings of studies, as well as safety issues. Finally, we highlighted current guidelines for clinical practice and future direction for further investigation.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
